The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCapital Regulatory News (CAPD)

Share Price Information for Capital (CAPD)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 103.00
Bid: 103.00
Ask: 105.50
Change: -1.00 (-0.96%)
Spread: 2.50 (2.427%)
Open: 104.50
High: 104.50
Low: 102.50
Prev. Close: 104.00
CAPD Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Expansion of Chrysos Corporation Global

14 Jul 2022 07:00

RNS Number : 3724S
Capital Limited
14 July 2022
 

For Immediate Release

14 July 2022

 

 

 

 

MSALABS Limited & Capital Limited

("MSALABS" & "Capital")

 

Expansion of Chrysos Corporation Global Partnership

MSALABS, a global provider of geochemical laboratory services for the exploration and mining sectors and a majority-owned subsidiary of Capital, is pleased to announce that it has expanded its global partnership with Chrysos Corporation ("Chrysos"). The partnership will see MSALABS, deploy 21 Chrysos PhotonAssay™ units across the globe by 2025.

Roll-out of initial six units proceeding on-track: In April 2021 MSALABS announced its global partnership with Chrysos and revealed the planned deployment of six PhotonAssay units across its global network. This rollout commenced with a unit at Barrick Gold's Bulyanhulu Gold Mine, Tanzania and represented the first Chrysos PhotonAssayTM unit deployment outside of Australia. MSALABS has continued the rollout with units now commissioned at the Morila Gold Mine, Mali (Firefinch) and in Val d'Or, Quebec, Canada. A fourth unit will arrive imminently in Yamoussoukro, Cote d'Ivoire with facility preparations well advanced. A fifth unit is ready for shipment to the Kibali Gold Mine, DRC (Barrick Gold) with the sixth unit due to begin installation in Timmins, Canada by the end of 2022.

A further 15 units rolled out over 2023 and 2024: MSALABS has committed to a further 15 Chrysos PhotonAssayTM units that will be rolled out over 2023 and 2024. MSALABS is currently engaged with multiple mining companies globally including most of the Top 10 and continues to see exceptional demand for this revolutionary new technology.

Chrysos PhotonAssayTM - A revolutionary technology: MSALABS has become an early adopter of Chrysos PhotonAssayTM as it delivers multiple advantages over the slower, more hazardous fire assay process. The PhotonAssay technology provides faster, safer, more accurate and environmentally-friendly analysis of gold, silver, copper and other elements. The process is significantly simpler than fire assay, dramatically improving the turnaround time for results and reducing the risk of human error, with the added benefit of being able to retain and retest samples. In addition, the use of X-rays avoids the high temperatures and harmful chemicals such as lead and acids involved in fire assay, making it more environmentally friendly with a lower carbon footprint.

Revenue outlook: Revenue guidance for MSALABS in 2022 remains ~$30 million which includes the rollout of the initial six Chrysos PhotonAssayTM units by year end, with each unit generating $3-5 million, depending on utilisation. Following the rollout of the further 15 units across 2023 and 2024, in conjunction with the expansion of the existing geochemistry business, MSALABS anticipates generating revenues in excess of $80 million per annum.

Capital will be announcing its trading update for the six months to 30 June on 19 July, which will include a conference call and question and answer session. The call will also be attended by Stuart Thomson, the CEO of MSALABS.

Commenting on the additional units, Stuart Thomson, MSALABS CEO said

'We are pleased to expand our relationship with Chrysos and to assist in the global rollout of its revolutionary technology. Over the past year, we have seen very strong demand for Chrysos PhotonAssay, and we expect this interest to continue to grow as our global mining customers not only gain confidence in its accuracy and reliability, but also benefit from the substantially improved turnaround time for results not possible with fire assay. 

In recent years we have grown our network significantly and now have 18 laboratories globally. Adding Chrysos PhotonAssay into our service offering is exciting for us and a key benefit for our customers."

 

Capital's Executive Chairman, Jamie Boyton, said:

'Having been only a small part of Capital's business following the acquisition of a controlling interest in 2019, MSALABS has seen exceptional expansion and quickly become a meaningful contributor to group revenues. We are pleased to see the extension of the relationship with Chrysos, which will continue to drive material growth over the coming years.'

 

- ENDS -

For further information, please visit Capital's website www.capdrill.com or contact:

 

Capital Limited

Jamie Boyton, Executive Chairman

Giles Everist, Chief Financial Officer

Conor Rowley, Investor Relations & Corporate Development Manager

 

+230 464 3250

investor@capdrill.com

Tamesis Partners LLP

Charlie Bendon

Richard Greenfield

+44 20 3882 2868

 

Stifel Nicolaus Europe Limited

Ashton Clanfield

Callum Stewart

Rory Blundell

 

+44 20 7710 7600

Berenberg

Matthew Armitt

Jennifer Wyllie

Detlir Elezi

+44 20 3207 7800

 

 

Buchanan

Bobby Morse

George Cleary

+44 20 7466 5000

capital@buchanan.uk.com

 

About Capital Limited

Capital Limited is a leading mining services company providing a complete range of drilling, mining, maintenance, and geochemical laboratory solutions to customers within the global minerals industry, focusing on the African markets. The Company's services include: exploration, delineation and production drilling; load and haul services; mining equipment hire and maintenance; and geochemical analysis. The Group's corporate headquarters are in Mauritius and it has established operations in Burkina Faso, Côte d'Ivoire, Egypt, Guinea, Kenya, Mali, Mauritania, Nigeria, Saudi Arabia and Tanzania.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCLXLFFLDLZBBK
Date   Source Headline
18th Apr 20247:00 amRNSQ1 2024 Trading Update
27th Mar 202411:11 amRNSIssue of Equity/Director PDMR/Total Voting Rights
14th Mar 20247:14 amRNSFinancial Results for FY 2023
14th Mar 20247:00 amRNS2023 Annual Report Published
13th Mar 20245:32 pmRNSTR-1 Notification of Major Holdings
13th Mar 20247:00 amRNSFY 2023 London Stock Exchange Presentation
19th Jan 20247:00 amRNSQ4 2023 Trading Update
21st Dec 20237:00 amRNSNevada Gold Mines (“NGM”) Contract Award
15th Nov 20237:00 amRNSAppointment of Non-Executive Director
31st Oct 20237:00 amRNSMSALABS Chrysos Barrick Capital Partnership
18th Oct 20237:00 amRNSQ3 2023 Trading Update
20th Sep 20237:00 amRNSNew Contracts Updates
4th Sep 202311:54 amRNSDirector Dealing
18th Aug 20233:33 pmRNSReplacement: Capital Ltd presentation on IMC
18th Aug 20231:34 pmRNSCapital Ltd presentation on IMC
16th Aug 20237:00 amRNSH1 2023 Results
14th Aug 20237:00 amRNSLondon Stock Exchange Presentation
19th Jul 20237:10 amRNSQ2 2023 Trading Update
7th Jul 20237:00 amRNSMSALABS Trading Update
29th Jun 20233:09 pmRNSLong Term Incentive Grant
28th Jun 20232:26 pmRNSDIRECTOR DEALING
26th Jun 20232:05 pmRNSPDMR Notification
23rd Jun 202311:38 amRNSResults of Placing of Existing Common Shares
23rd Jun 20237:00 amRNSProposed Placing of Existing Common Shares
12th Jun 20237:00 amRNSNew Contract Award & Finance Update
18th May 20232:22 pmRNSResult of AGM
3rd May 20237:00 amRNSDirect Investment Update
20th Apr 20237:00 amRNSQ1 2023 Trading Update
18th Apr 202311:43 amRNSCommencement of Trading on the OTCQX Market
13th Apr 20234:02 pmRNSNotice of AGM and Proxy Form
5th Apr 202310:13 amRNSNotification of Major Holdings
3rd Apr 20231:00 pmRNSIssue of Equity/Director PDMR/Total Voting Rights
27th Mar 20237:00 amRNSFY2022 Annual Report
16th Mar 20237:00 amRNSPRELIMINARY FULL YEAR FINANCIAL RESULTS
7th Mar 202310:56 amRNSNotification of Major Holdings
6th Mar 20237:00 amRNSMSALABS Trading Update
19th Jan 20237:00 amRNSFY 2022 Trading Update
23rd Nov 20226:15 pmRNSDirector Share Purchase
9th Nov 20227:00 amRNSNotification of Major Holdings
1st Nov 20227:00 amRNSAnnouncement of CFO Transition
18th Oct 20227:00 amRNSQ3 2022 Trading Update
6th Sep 20227:00 amRNSNew Contract Award
2nd Sep 20227:00 amRNSAppointment of CEO
18th Aug 20227:00 amRNSInterim Results
19th Jul 20227:00 amRNSQ2 2022 Trading Update
14th Jul 20227:00 amRNSExpansion of Chrysos Corporation Global
30th Jun 20227:00 amRNSNew Contract Awards
15th Jun 20224:31 pmRNSLong Term Incentive Grant
28th Apr 20222:50 pmRNSResults of Annual General Meeting
21st Apr 20227:00 amRNSQ1 Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.